仟源医药（300254）公告，子公司江苏嘉逸医药有限公司收到国家药品监督管理局签发的依巴斯汀《化 学原料药上市申请批准通知书》。依巴斯汀适用于伴有或不伴有过敏性结膜炎的过敏性鼻炎及慢性特发 性荨麻疹的对症治疗。依巴斯汀原研为INDUSTRIAS FARMACEUTICAS ALMIRALL,S.A.，子公司杭 州仟源保灵药业有限公司的依巴斯汀片已通过一致性评价，该品种已进入国家医保目录乙类。依巴斯汀 原料药获批上市后，将进一步降低制剂产品的生产成本，增强产品的市场竞争力。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is actively pursuing innovation-driven development strategies, focusing on R&D, market expansion, and strategic acquisitions to enhance its position in the pharmaceutical industry [1][2][3][4][5][6][7][8] Group 1: Innovation and R&D - The company is increasing its R&D investment, with a projected total of approximately 277 million yuan for 2024, representing a year-on-year growth of about 96% [6] - Lianhuan Pharmaceutical has established multiple R&D platforms and is focusing on innovative drug development in areas such as cardiovascular, urology, and oncology, with six innovative drugs in the pipeline [4][5] - The company has received multiple drug registration certificates in 2023, including for products like Olmesartan and Furosemide, enhancing its product portfolio [5] Group 2: Strategic Acquisitions - Lianhuan Pharmaceutical's subsidiary, Yangzhou Lianhuan Investment Co., Ltd., plans to acquire a 51% stake in Sichuan Longyi Pharmaceutical for 70.38 million yuan, aiming to strengthen its market presence in Southwest China [2][3] - Earlier in January, the company acquired a 54% stake in Changle Pharmaceutical for 183.26 million yuan, further expanding its portfolio and market reach [3] - The company is committed to continuous investment and acquisition strategies to integrate quality resources and enhance its industry position [3] Group 3: Production Capacity Expansion - Lianhuan Pharmaceutical is increasing the registered capital of its subsidiary, Lianhuan (Anqing) Co., Ltd., from 50 million yuan to 130 million yuan to enhance its production capabilities [7][8] - The Anqing facility is crucial for the company's manufacturing layout and is expected to produce various formulations, including oral solutions and topical preparations [8] - The company has received a drug production license for the Anqing facility, which will contribute to its ability to supply high-quality products [7][8] Group 4: Financial Performance and Shareholder Returns - The company has maintained a consistent dividend payout ratio of 30% over the years, with total dividends of approximately 43.07 million yuan, 42.82 million yuan, and 25.41 million yuan from 2022 to 2024 [8] - Analysts predict that through its strategic initiatives, the company's overall revenue could exceed 4 billion yuan in 2023 [3]